Full Year 2025 Cipla Ltd Earnings Call Transcript
Key Points
- Cipla Ltd (BOM:500087) achieved a significant milestone with its One-India business surpassing INR11,000 crores in revenue, showcasing strong domestic market performance.
- The North America segment saw remarkable progress with three key new drug approvals, contributing to an all-time high annual revenue of $934 million.
- The One-Africa business grew impressively by 15% year on year during the quarter, with a full-year growth of 12% in USD terms, outpacing market growth.
- Cipla Ltd (BOM:500087) expanded its presence in the Indian Pharmaceutical Market (IPM) by adding four brands with revenues exceeding INR100 crores, bringing the total to 26 brands.
- The company maintained a strong EBITDA margin of 22.8% for the quarter and 25.9% for the year, exceeding guidance and reflecting operational efficiency.
- The guidance for FY26 EBITDA margin is slightly lower than the previous year, attributed to the loss of exclusivity for generic Revlimid.
- Despite strong performance, the overall market growth rate for the Indian Pharmaceutical Market has slowed from 10-12% to 8-10%, impacting future growth expectations.
- The trade generics business did not achieve double-digit growth in the quarter, unlike the Consumer Health segment.
- Cipla Ltd (BOM:500087) faces potential challenges in the US market due to evolving pharmaceutical tariffs and executive orders, although current impacts are minimal.
- The company's R&D investments, while strategic, remain capped at 6-6.5% of revenue, potentially limiting rapid innovation and expansion in high-growth areas.
Ladies and gentlemen, good day, and welcome to the Cipla Limited Q4 FY25 Earnings Call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Diksha Maheshwari, Lead Investor Relations from Cipla Limited. Thank you, and over to you, ma'am.
Thank you, Rutuja. Good afternoon, and a very warm welcome to Cipla's Q4 FY25 Earnings Call. I'm Diksha Maheshwari from the Investor Relations team at Cipla.
Let me draw your attention to the fact that on this call, our discussion will include certain forward-looking statements, which are predictions, projections or other estimates about future events. These estimates reflect management's current expectations of the future performance of the company.
Please note that these estimates involve several risks and uncertainties that could cause our actual results to differ materially from what is expressed or implied. Cipla does not undertake any obligation to publicly update any forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
